NASDAQ · NTRBWHealthcareOrthopedic & Surgical Supplies

Nutriband Inc. Warrant financials

$1.66+26.72%
Close Sep 28, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

Fiscal yearFY26
Jan 31
FY25
Jan 31
FY24
Jan 31
FY23
Jan 31
FY22
Jan 31
Revenue$2.0M$2.1M$2.1M$2.1M$1.4M
Gross profit$566.3K$743.3K$862.1K$750.4K$504.3K
Gross margin27.8%34.7%41.3%36.1%35.5%
Operating income-$8.3M-$10.3M-$4.9M-$4.5M-$6.1M
Net income-$30.0M-$10.5M-$5.5M-$4.5M-$6.4M
Net margin−1475.2%−489.9%−263.0%−215.6%−448.1%
Diluted EPS$-2.58$-0.99$-0.55$-0.42$-0.64
EBITDA-$8.1M-$6.4M-$4.6M-$3.8M-$3.6M
Operating cash flow-$5.1M-$4.6M-$3.5M-$3.0M-$2.8M
Free cash flow-$5.1M-$4.7M-$3.6M-$3.1M-$2.9M
Diluted shares11.6M10.6M9.9M10.6M9.9M

Balance sheet

Period endJan 31Jan 31Jan 31Jan 31Jan 31
Cash & equivalents$4.6M$4.3M$492.9K$2.0M$4.9M
Short-term investments$0.00$0.00$0.00$0.00—
Total debt$164.7K$186.3K$207.0K$120.2K$115.2K
Total assets$7.5M$7.5M$7.5M$9.5M$12.7M
Total liabilities$868.4K$1.0M$1.1M$883.4K$880.4K
Shareholders' equity$6.7M$6.4M$6.4M$8.6M$11.9M

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology